dr. georgina long on dabrafenib and trametinib in braf-mutated melanoma
Published 8 years ago • 979 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:05
georgina long on treating melanoma with dabrafenib plus trametinib
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
1:37
dr. arkenau on dabrafenib combined with trametinib for braf-mutated melanoma
-
2:51
combi-ad: long-term follow-up of dabrafenib and trametinib in braf-mutated melanoma
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
14:55
prof georgina long ao - the promising future of advanced melanoma treatment
-
2:35
dr. georgina long on the treatment of melanoma with emerging targeted therapies
-
6:05
4 questions with professor georgina long (medical oncology)
-
5:15
managing braf inhibitor associated skin toxicity
-
4:19
braf: a new target to treat in lung cancer
-
1:17
dr. long on the rationale for the phase 3 combi-i trial in braf v600–mutant melanoma
-
3:06
combi-d: phase 3 trial of dabrafenib plus trametinib in braf v600e/k-mutated melanoma
-
3:05
dabrafenib and trametinib: a promising combination for the treatment of melanoma
-
2:56
treating braf v600e-mutant nsclc with dabrafenib and trametinib
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
1:40
dr. robert on the phase iii combi-v study in braf-mutant melanoma
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
2:46
long-term outcomes with dabrafenib plus trametinib in braf v600-mutant melanoma
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
0:56
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma